Literature DB >> 22760213

Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer.

Thomas Decker1, Gerhard Fischer, Wolfgang Bücke, Philipp Bücke, Frank Stotz, Andreas Grüneberger, Martina Gropp-Meier, Günther Wiedemann, Christine Pfeiffer, Christian Peschel, Katharina Götze.   

Abstract

BACKGROUND: Although progress has been made in establishing prognostic factors in breast cancer, there remains an urgent need for better prognostic and predictive scores for patients with early breast cancer. The important role of the immune system in controlling cancer progression is widely accepted. Regulatory T cells (T-regs) constitute a specialized T cell subset, which play an essential role in sustaining self-tolerance by negatively regulating immune responses. Increased frequencies of T-regs have been reported in the micromilieu of a variety of malignancies including breast cancer. However, little is known about the role of T-regs in the peripheral blood of cancer patients.
METHODS: We analyzed T-reg numbers in the peripheral blood of 292 patients with newly diagnosed early breast cancer by flow cytometry (CD4(+)CD25(+)CD127(low) cells) prior to planned breast surgery.
RESULTS: Absolute T-reg numbers/µl varied from 4 to 212/µl. No difference could be detected in T-reg numbers between nodal negative and nodal positive, well and poorly differentiated or small and locally advanced cancers. However, T-reg numbers of Her-2/neu-positive patients were higher than in samples from patients with hormone receptor positive, Her-2/neu-negative cancers. In contrast, numbers of T-regs were not increased in triple negative patients. In addition, T-reg numbers were higher in patients with invasive ductal carcinomas as compared to invasive lobular cancers.
CONCLUSIONS: Increased numbers of circulating T-regs may contribute to the higher metastatic potential of Her-2/neu-positive cells. A potential role as a prognostic or predictive parameter is currently being analyzed in a larger cohort of patients with sufficient follow-up.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22760213     DOI: 10.1007/s00432-012-1258-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  37 in total

1.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

Authors:  Michael Gobert; Isabelle Treilleux; Nathalie Bendriss-Vermare; Thomas Bachelot; Sophie Goddard-Leon; Vanessa Arfi; Cathy Biota; Anne Claire Doffin; Isabelle Durand; Daniel Olive; Solène Perez; Nicolas Pasqual; Christelle Faure; Isabelle Ray-Coquard; Alain Puisieux; Christophe Caux; Jean-Yves Blay; Christine Ménétrier-Caux
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

Review 2.  Early breast cancer.

Authors:  John R Benson; Ismail Jatoi; Martin Keisch; Francisco J Esteva; Andreas Makris; V Craig Jordan
Journal:  Lancet       Date:  2009-04-25       Impact factor: 79.321

3.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

4.  Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery.

Authors:  Ausilia Sellitto; Gennaro Galizia; Umberto De Fanis; Eva Lieto; Anna Zamboli; Michele Orditura; Ferdinando De Vita; Riccardo Giunta; Giacomo Lucivero; Ciro Romano
Journal:  J Clin Immunol       Date:  2011-09-14       Impact factor: 8.317

Review 5.  Re-purposing cancer therapeutics for breast cancer immunotherapy.

Authors:  Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2012-03-28       Impact factor: 6.968

6.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.

Authors:  Wei Tan; Weizhou Zhang; Amy Strasner; Sergei Grivennikov; Jin Q Cheng; Robert M Hoffman; Michael Karin
Journal:  Nature       Date:  2011-02-16       Impact factor: 49.962

Review 7.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

Review 8.  Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.

Authors:  Mario P Colombo; Silvia Piconese
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 9.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

Review 10.  Differences in tumor regulatory T-cell localization and activation status impact patient outcome.

Authors:  Christine Ménétrier-Caux; Michael Gobert; Christophe Caux
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

View more
  10 in total

1.  CD4+CD25(high), CD8+CD28- cells and thyroid autoantibodies in breast cancer patients.

Authors:  Oğuz Biylgi; Bülent Karagöz; Orhan Türken; Mustafa Gültepe; Alpaslan Özgün; Tolga Tunçel; Levent Emirzeoğlu; Serkan Çelik; Tuba Müftüoğlu; Emin Gökhan Kandemir
Journal:  Cent Eur J Immunol       Date:  2014-10-14       Impact factor: 2.085

Review 2.  Towards a commercial process for the manufacture of genetically modified T cells for therapy.

Authors:  A D Kaiser; M Assenmacher; B Schröder; M Meyer; R Orentas; U Bethke; B Dropulic
Journal:  Cancer Gene Ther       Date:  2015-01-23       Impact factor: 5.987

3.  Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.

Authors:  M Mego; H Gao; E N Cohen; S Anfossi; A Giordano; T Sanda; T M Fouad; U De Giorgi; M Giuliano; W A Woodward; R H Alvarez; V Valero; N T Ueno; G N Hortobagyi; M Cristofanilli; J M Reuben
Journal:  J Cancer       Date:  2016-06-03       Impact factor: 4.207

Review 4.  Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications.

Authors:  Monica Reis; Justyna Ogonek; Marsela Qesari; Nuno M Borges; Lindsay Nicholson; Liane Preußner; Anne Mary Dickinson; Xiao-Nong Wang; Eva M Weissinger; Anne Richter
Journal:  Front Immunol       Date:  2016-11-14       Impact factor: 7.561

Review 5.  Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.

Authors:  Nehad M Ayoub; Kamal M Al-Shami; Rami J Yaghan
Journal:  Breast Cancer (Dove Med Press)       Date:  2019-01-17

Review 6.  Surgical stress and cancer progression: the twisted tango.

Authors:  Zhiwei Chen; Peidong Zhang; Ya Xu; Jiahui Yan; Zixuan Liu; Wayne Bond Lau; Bonnie Lau; Ying Li; Xia Zhao; Yuquan Wei; Shengtao Zhou
Journal:  Mol Cancer       Date:  2019-09-02       Impact factor: 27.401

7.  The Multifaceted Role of Regulatory T Cells in Breast Cancer.

Authors:  Kevin Kos; Karin E de Visser
Journal:  Annu Rev Cancer Biol       Date:  2020-12-04

8.  Vascular endothelial growth factor expression and T-regulatory cells in premenopausal breast cancer.

Authors:  Francesco Recchia; Giampiero Candeloro; Stefano Necozione; Giovambattista Desideri; Alisia Cesta; Laura Recchia; Silvio Rea
Journal:  Oncol Lett       Date:  2013-01-18       Impact factor: 2.967

9.  Analysis of the Heterogeneity of CD4+CD25+ T Cell TCR β CDR3 Repertoires in Breast Tumor Tissues, Lung Metastatic Tissues, and Spleens from 4T1 Tumor-Bearing BALB/c Mice.

Authors:  Teng Zhang; Fangfang Duan; Danhua Su; Long Ma; Jiezuan Yang; Bin Shi; Xiaoyan He; Rui Ma; Suhong Sun; Xinsheng Yao
Journal:  J Immunol Res       Date:  2020-09-24       Impact factor: 4.818

10.  Frequency of CD4+ regulatory T cells, CD8+ T cells, and human papilloma virus infection in Egyptian Women with breast cancer.

Authors:  Amany M Tawfeik; Ahmed Mora; Ahmed Osman; Manar M Moneer; Nabila El-Sheikh; Mohamed Elrefaei
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.